An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase.

Abstract

BACKGROUND In the Global Utilization of Streptokinase and tPA for Occluded coronary arteries (GUSTO) trial, patients with myocardial infarction who were treated with tissue plasminogen activator (tPA) had a 6.3% 30-day mortality, compared with a mortality of 7.3% among those treated with streptokinase, despite a greater risk of intracranial hemorrhage with… (More)

Topics

Cite this paper

@article{Kent2002AnID, title={An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase.}, author={David M. Kent and Rodney A. Hayward and John L. Griffith and Sandeep S Vijan and Joni R. Beshansky and Robert M. Califf and Harry P. Selker}, journal={The American journal of medicine}, year={2002}, volume={113 2}, pages={104-11} }